top of page

OC CONTRIBUTES TO MAJOR JOURNAL


Oncology Consultants contributed to an important safety study of Nivolumab (Opdivo), published in The Lancet Oncology, March the 1st 2015. This new drug has a meaningful and manageable safety profile in previously treated patients with advanced, refractory, squamous nonsmall cell lung cancer. The FDA approved Nivolumab, a fully human IgG4 PD-1 immune check inhibitor antibody, for this indication.

The Doctors & Staff of Oncology Consultants are pleased to help advance oncology treatments from research to practice through our participation in the Checkmate Protocol. (NCT01721759).


Recent Posts